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Oral and intravenous bretylium disposition
To compare the oral and intravenous disposition of bretylium tosylate in man, 10 normal male
subjects were randomly assigned single doses of 5 mg lkg bretylium tosylate either orally or
intravenously and crossed over 2 wk later to the opposite route (20 studies). Each experiment
included sampling for drug in serum and urine over 48 hr. Bretylium tosylate was assayed by
gas chromatography. Kinetic analysis provided the following mean [coefficient of variation]
results: 100F!'o, 22.6% [40.2%]; CW, 300 mllmin [27.8%]; CL;.", 1,268 mglmin [54.8%]; Cn;
299 mllmin [31.9%];j; 101% [8.7%]; Vliss, 3.371/kg [30.5%]; 1..[,10.0510 [12.8%]; 1..);°0.115
[52.7%] hr:'; elimination half-life (tl/z) after intravenous bretylium tosylate, 13.6 hr, and after
oral bretylium tosylate, 6.0 hr (harmonic means). Bretylium tosylate binding to plasma proteins
in normal volunteer samples was found to be negligible. The results indicate extensive tissue
binding of bretylium tosylate. Oral doses of bretylium tosylate are only partially absorbed.
Bretylium tosylate is eliminated entirely by the kidneys as unchanged drug. The greater renal
clearance after oral than intravenous bretylium tosylate, and the greater elimination rate
constant and shorter oral bretylium tosylate t Vz are of interest but no explanation is available.
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Bretylium tosylate, a quaternary ammonium
compound, exerts marked antifibrillatory ef-
fects in animals.v :1 Clinical experience has
suggested similar effects in man.v 6, 15, 24 The
drug was released for general use in 1978
for life-threatening ventricular arrhythmias that
failed to respond to conventional therapy. 10, 16
Oral use of the drug is currently investigational.
Early clinical experience suggests more wide-
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spread use of bretylium in both short- and long-
term settings. 16
Bretylium effects a biphasic cardiovascular
response ." 12, 20 Local norepinephrine release
from adrenergic nerve endings causes an initial
rise in blood pressure and a positive inotropic
effect on the heart after short-term dosing,
which is followed by a fall in blood pressure
and relative bradycardia, the result of adren-
ergic neuronal blockade, The major electro-
physiologic effect of bretylium is prolongation
of the action potential and effective refractory
period of specialized tissues of the heart. 7, 11
Bretylium is the prototype of a separate, unique
class of antiarrhythmic drugs.!"
Bretylium kinetics in man is poorly under-
stood because of difficulty in developing a
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Table I. Coefficients of variation [CV (%)]* obtained from duplicate assays
Variable I Range I n '--M-e-a-n-- _
*cv (%) = MSO x 100, where SO = , j l2d2, d is the difference between duplicate assays, n = number of samples, and 2n = number
ean 'J n
of assays.
Definitions of kinetic parameters
100Fpo: Percent of dose reaching circulation
unchanged after oral administration
f: Fraction of drug reaching circulation
that is ultimately excreted un-
changed in the urine
en: Total body clearance of drug after
intravenous administration
CW: Renal clearance of drug after intra-
venous administration
Clro: Renal clearance of drug following
oral administration
Vdss : Steady-state volume of distribution
Vd area: Volume of distribution area
AP: Apparent elimination rate constant
after intravenous administration
A';o: Apparent elimination rate constant
after oral administration
(AUC)I\: Area under serum concentration-
time curve from zero to infinite time
after single intravenous infusion
(AUC)po: Area under serum concentration-
time curve from zero to infinite time
after single oral dose
reliable assay of serum drug concentra-
tions.P: 14, 17, 23 The recent development of a
sensitive and reliable gas chromatographic
assay in our laboratory has enabled us to evalu-
ate bretylium kinetics in man.P The objectives
of our study were to determine bretylium kinet-
ics in normal subjects in serum and urine after
single intravenous doses, and to compare bre-
tylium disposition in the same subjects after
single oral doses.
Methods
Single doses of bretylium tosylate were given
both intravenously and orally in a random se-
quence separated by a 2-wk interval to 10
healthy men, aged 20 to 47 yr (x, 27.7 ± 9.2;
median, 25 yr). Subjects were in normal health
as ascertained by history and physical examina-
tion, and weighed between 65 and 85 kg
(x ± SD = 68.3 ± 7.3 kg), which was within
10% of normal weight for height and age. Sub-
jects were excluded if they had received any
medications within the previous 2-wk period.
Alcoholism and drug abuse, resting hypoten-
sion (less than 90 mm Hg systolic blood pres-
sure) or bradycardia (less than 50 beats/min),
and known idiosyncrasy towards bretylium or
other quaternary ammonium compounds were
further exclusion criteria. The approved intrave-
nous formulation of bretylium tosylate (Amar-
Stone) was used for all intravenous and oral
studies.
Experimental protocol. After initial screen-
ing, and an overnight fast beginning at 10 P.M.,
subjects were admitted to the Clinical Research
Center of the University of Michigan. Detailed
history and physical examination as well as
electrocardiogram were obtained.
A heparin lock was inserted in one arm for
drawing blood samples. In patients receiving
the drug intravenously, a peripheral line was
started in the opposite arm and kept open with a
dextrose infusion. After initial vital signs and
blood samples were obtained, a total of 5 mg/kg
of bretylium tosylate was delivered at a constant
rate over 30 min by a calibrated Harvard infu-
sion pump. The drug was administered in 50 ml
of 5% dextrose. Blood pressure and heart rate
were measured every 5 min for 30 min, then at
V2- to l-hr intervals for 6 hr and again at 8,
12, 16, and 24 hr. Constant electrocardio-
graphic monitoring was performed for the first
12 hr. Blood was drawn just before drug infu-
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CW Ct;.V Clf.°
Vdss
lOOFPo ISubject (%) f (ml lmin) (ml lmin] (mllmin) I I1kg
1 32.1 0.98 263 257 997 180 2.77
2 12.5 0.88 475 417 610 314 4.52
3 27.3 1.03 362 372 1,148 255 3.90
4 11.6 1.09 232 253 1,232 161 2.50
5 22.4 1.05 233 245 1,283 178 2.58
6 36.6 1.01 222 224 1,269 202 2.31
7 30.4 0.91 348 315 2,642 257 3.64
8 24.6 1.02 160 163 2,292 142 2.21
9 12.7 0.98 397 390 599 312 5.11
10 15.6 1.19 302 360 606 265 4.15
Mean 22.6 1.01 299 300 1,268 227 3.37
CV (%)* 40.2 8.7 31.9 27.8 54.8 27.4 30.5
'See footnote to Table I for explanation of CV (%).
sion and at 0,6,15,30, and 45 min, and 1,1.5,
2, 3,4,6,8, 12, 16, 24, and 48 hr, and at 30
min after the end of infusion. Seven milliliters
of blood were obtained on each occasion in un-
coated tubes. Serum, separated from clot by
centrifugation, was frozen until assayed.
Patients receiving oral doses took 5 mg/kg
bretylium tosylate solution mixed in a glass of
orange juice at 0 time. Initial blood sampling
and vital signs were checked at 30 min, 1 hr,
and thereafter as for the intravenous protocol.
Subjects receiving oral doses on the first ad-
mission received intravenous bretylium 2 wk
later, and those receiving intravenous drug on
the first admission received the oral dose on the
second admission.
For each experiment, all urine was collected
for 48 hr and fractionated at 6, 12, 24, and 48
hr. Two glasses of water (480 ml) were given lf2
hr before drug. Two additional liters of oral
fluid were encouraged within the first 24-hr pe-
riod. During drug infusion and for the first 12 hr
thereafter, subjects were kept supine in bed. For
the subsequent 12 hr, they remained primarily
in bed, but were allowed to stretch and use the
bathroom if there was no postural hypotension.
Patients were discharged ambulatory at 24 hr, to
return at 48 hr for follow-up blood and urine
sampling.
Twelve-lead electrocardiograms were ob-
tained prior to drug and at the end of 24 hr
before discharge. The following laboratory tests
were obtained before drug infusion and 24
hr before discharge: hemoglobin, hematocrit,
white blood count, platelet estimate, elec-
trolytes, sugar, and urea nitrogen, creatinine,
calcium, uric acid, total protein, albumin, al-
kaline phosphatase, total bilirubin, aspartate
aminotransferase, urine creatinine concentra-
tion, and urinalysis.
Plasma protein binding. To assess bre-
tylium plasma protein binding, 14C-bretylium
tosylate was added to samples of human plasma
at 30, 3, 0.3, and 0.03 fLg/ml. Triplicate sam-
ples were analyzed at each concentration for
fraction of free drug and of bound drug.
Bretylium assay. Bretylium was assayed by
gas chromatography using the method of Patter-
son et al. 22
Statistical methods. Group means of vari-
ables measured before and after drug are given
together with standard deviations (SD) as x ±
SD. Means followed by coefficients of variation
are given as mean [CV%]. Differences in
means at two times (i.e., before and after drug)
were analyzed for significance using Student's
paired t test. Differences in the means of vari-
ables from two groups (i.e., oral and intrave-
nous drug) at the same time point were com-
pared by the unpaired Student's t test. A prob-
ability less than or equal to 0.05 was taken as
significant. Kinetic parameters were calculated
as noted in the Appendix.
Results
Clinical responses to drug administration.
Intravenous bretylium was followed by ex-
pected cardiovascular effects." Infusion was
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Fig. 1. Urinary excretion-time curve for bretylium
after intravenous (upper curve) and oral dosing
(lower curve). Values are plotted as x ± SD of frac-
tion dose in urine at indicated times.
Individual and mean kinetic parameters, along
with respective CVs, are given in Table II for
the 10 subjects. The mean renal clearance for
bretylium after oral doses (CI~O = 1,268 mil
min) was greater than the mean renal clearance
after intravenous doses (Cl'rv = 300 mil min) by
paired t test (p < 0.01). The ratio of the means
of CI~o/CI\Y equaled 4.2.
The differences in disposition of oral and in-
travenous doses were also evident in the appar-
ent elimination rate constants. The mean elimi-
nation rate constant after oral doses, A~o =
0.115 he 1, was greater (p < 0.01, paired t test)
than after intravenous doses, namely A)V =
0.0510 hr- 1 • The ratio of the means of Ajo/\V
equaled 2.3.
The change in renal clearance of bretylium
with change in route of administration necessi-
tated the use of a special equation (Appendix,
equation 6) to estimate bioavailability (efficien-
cy of absorption) after oral doses, symbolized
by 100Fpo' Based on this calculation, an aver-
age of only 22.6% [40.2%] of the oral dose
(range 11.6% to 32.1 %) of bretylium tosylate
was absorbed.
Although urinary excretion of bretylium was
not quite asymptotic at 48 hr when urine sam-
pling ceased (Fig. 1, Table III), the ratio
PO
IV
1.0
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35.1 36.6 12.8 52.7
associated with symptoms of catecholamine re-
lease (anxiety, excitement, or flushing) in six
of ten subjects. Blood pressure (systolic/dia-
stolic) rose from 115.8 ± 10.1177.6 ± 9.5 to
144.8 ± 22.3/97.4 ± 14.4 mm Hg (p < 0.01)
at end of infusion. Heart rate rose from
62.4 ± 7.6 to 67.7 ± 8.7 beats/min. Blood
pressure then declined at 30 min and returned to
baseline by 1 hr after infusion. Postural symp-
toms such as dizziness were reported in four
subjects during the first several hours after in-
fusion, and in five a fall in systolic pressure to
less than 100 mm Hg occurred at 12 hr on stand-
ing. Nasal congestion was reported in seven,
and was usually noted within I to 2 hr of infu-
sion and resolved gradually over several hours.
Transient headache and nausea were each re-
ported in two patients towards the end of
infusion.
After oral dose, blood pressure changes,
signs of catecholamine release, and other side
effects were small or absent. Systolic blood
pressure and heart rate increased at 30 min only:
104.0 ± 10.2 to 119.0 ± 9.4 mm Hg and
62.4 ± 7.1 to 67.2 ± 5.6beats/min(p < 0.05
for each change).
Reproducibility of drug assay. Coefficients
of variation (CVs) obtained from duplicate as-
says for bretylium in serum and urine are pre-
sented in Table 1. There was excellent repro-
ducibility in all concentration ranges; CVs were
4.2% to 6.0% except when urinary concentra-
tion was under 14 ILg/ml, in which case CV
was 10.1 %.
Kinetic parameters for bretylium tosylate.
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Table III. Urinary excretion of bretylium
Amounts of bretylium base* excreted in urine (mg)
Oral (hr) Intravenous (hr)
Subject 0-6 I 6-12 I 12-24 I 24-48 I 0-48 0-6 I 6-12 I 12-24 I 24-48 I 0-48
1 13.2 20.5 11.8 7.5 53.0 38.0 27.0 41.0 54.0 160
2 15.1 2.5 1.2 0.9 19.7 46.0 25.8 38.7 41.8 152
3 22.0 12.3 2.2 9.7 46.2 52.8 33.4 39.4 42.8 168
4 6.0 7.7 3.9 2.5 20.1 44.5 37.1 36.8 56.9 175
5 26.0 6.6 3.1 4.1 39.8 55.4 54.1 35.5 36.7 174
6 63.1 1.3 4.2 3.1 71.7 88.3 55.1 55.0 t 198
7 20.0 11.9 9.4 12.6 53.9 29.0 22.7 38.6 44.1 134
8 29.3 5.1 5.4 2.7 42.5 55.9 30.0 32.0 34.0 152
9 12.2 1.27 1.25 4.7 19.4 38.1 16.5 46.3 33.7 135
10 15.7 7.0 4.6 1.1 28.4 72.2 39.5 17.5 30.0 159
Mean 22.3 7.6 4.7 4.9 39.5 52.0 33.3 38.1 41.6 161
CY (%):j: 71.5 78.0 73.0 79.0 44.5 33.7 34.6 25.3 22.1 12
*Bretylium base equals 0.52% of bretylium tosylate by weight.
tNo sample.
:j:See footnote to Table I for explanation of CV (%).
Table IV. Mean serum concentrations and
coefficients of variation (eV)
Oral Intravenous
Time* Mean I CV Mean I CV(hr) (nglml) (%)t (nglml) (%)t
0.1 + 1,567 24.5
0.25 :j: 1,375 24.6
0.5 17 84 1,231 26.2
0.75 :j: 1,109 25.8
1 34 118 955 25.0
1.5 39 84 883 26.5
2 45 67 778 27.2
3 48 42 597 45.9
4 46 64 548 37.5
6 34 52 431 39.7
8 28 83 343 45.7
12 18 51 237 48.6
16 12 54 162 54.1
24 5.4 77 96 53
48 0.9 28 49
*Time after oral dose or time measured from the end of the in-
fusion for intravenous doses.
tSee footnote to Table I for explanation of CV (%).
:j:Samplesnot taken.
f = Cl~V ICl\; indicated that if urine had been
collected long enough, an average of 101%
[8.7%], the entire dose (range 88% to 119%),
would have been excreted (Table II). This
strongly suggests that most, if not all, of the
subjects did not metabolize bretylium tosylate.
The very large estimated volumes of distri-
bution (Vd ss , Vd area) of 3.4 and 5.3l!kg (Table
II) suggest that bretylium is highly bound to
tissue.
Creatinine clearance (CrCl) after intravenous
doses averaged 112 ± 20 mJlmin during day 1
(inpatient), and 103 ± 19 mJlmin during day 2
(outpatient). After oral doses, CrCl was 120 ±
27 mJlmin during day 1 (inpatient) and 114 ±
19 mJlmin during day 2 (outpatient). Differ-
ences in CrCl by route of administration were
not significant. The ratio of clearances of bre-
tylium to creatinine were: Cllrv ICrCJ!V =
2.75 ± 0.83, and Cl~o/CrClPo = 11.00 ±
6.30. The ratios varied widely, especially after
oral doses, and there was no correlation be-
tween individual clearances of the two sub-
stances.
Plasma protein binding of bretylium tosy-
late. In contrast to its marked tissue-binding
properties, bretylium did not bind at all to
plasma proteins. Plasma binding was tested in
samples from a normal human and found to be
negligible at four plasma drug concentrations:
30, 3, 0.3, and 0.03 fLg/ml. The fraction of free
drug determined at the three higher plasma con-
centrations averaged 99% [3.9%] free. At the
lowest drug concentration, 0.03 fLg/ml, binding
to plasma protein was also negligible, but with a
larger coefficient of variation attributed to the
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Fig. 2. Mean serum concentration-time curves for bretylium after intravenous (upper curve) and
oral dosing (lower curve). Means are plotted together with SD.
extremely low radioactive count rate at this low
drug concentration.
Serum elimination curve. Mean serum con-
centrations after oral and intravenous bretylium
in 10 patients (20 experiments) are given for
various times between 0.1 and 48 hr in Table IV
and Fig. 2. Representative data for an indi-
vidual patient are presented in Fig. 3 for both
intravenous and oral administration. Despite
rapid decline in serum bretylium concentration
(Cs) in the first 3 hr after intravenous doses,
CVs were remarkably small (ca 25%) but there
were extremely large CVs (67% to 118%) dur-
ing the first 2 hr after oral doses. Later time
points also display greater CVs for oral than for
intravenous doses. Rapid, early fluctuations in
serum bretylium concentrations were not un-
common after oral doses (Fig. 3) but were not
present after intravenous doses. These varia-
tions greatly exceeded those attributable to the
assay, and suggest differences in initial han-
dling of oral drug. Intestinal secretion of drug,
uneven absorption, or other explanations may
apply, but these mechanisms were not ad-
dressed in this study.
Urinary excretion of bretylium. Fractional
and total bretylium base excreted in the urine
(mg) within 48 hr are given in Table III for
individual subjects receiving oral and intrave-
nous doses. The three- to fourfold difference in
mean CV (44.5% and 12%) in excretion after
oral than after intravenous administration is
noteworthy. Assuming negligible bretylium me-
tabolism, this implies substantial variation in
oral absorption. The ratio of urinary recovery
after oral and intravenous doses (39.5/161 =
0.245) is internally consistent with calculated
mean oral fractional absorption (Fpo = 0.226,
Table 11).
Peak serum concentrations of drug. The
peak serum bretylium concentration and time of
peak after oral as well as intravenous doses are
given by individual subject in Table V. Of note
is the wide range of time to peak after oral
doses, ranging from I to 8.5 hr, with a mean of
3.05 [72%] hr. Peak concentration averaged 76
[49%] ng/m!. Mean peak concentration of bre-
tylium at the end of 0.5 hr intravenous infusion
was 1,896 [24.7%] ng/rnl, 28 times that of the
peak after oral drug.
Areas under serum concentration -time
curves. Table VI compares the areas under in-
dividual and group concentration-time curves
for 0 to 48 hr with those estimated for the inter-
474 Anderson et at. Clin, Pharmacol . Ther,
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2000 the 24- and 48-hr values, to estimate the elimi-
nation rate constants. The mean elimination rate
constant of 0.115 hr" after oral administration
corresponds to an elimination tl/z of 6.0 hr,
while the mean rate constant of 0.0510 he l
after intravenous dosing corresponds to an elim-
ination tVz of 13.6 hr (harmonic mean).
Clinical and laboratory responses after
bretylium. Biochemical, hematologic, and
electrocardiographic testing before and 24 hr
after drug showed few changes except for evi-
dence of hemoconcentration after both intrave-
nous and oral dosing. Hemoconcentration was
reflected by small increases in total protein, al-
bumin, hemoglobin, hematocrit, and red blood
cell concentration. Hemoglobin, for example,
rose from 14.7 ± 1.0 to 16.3 ± 1.2 gm (p <
0.01). Urine specific gravity did not change.
The only significant biochemical change was a
small decrease in chloride concentration
(107.1 ± 1.6 to 105.3 ± 1.5 mEq/l) (p = <
0.05). Creatinine ranged from 0.7 to 1.2 mg/dl
(x, 0.99 ± 0.13) before drug, and urea nitrogen
from II to 20 mg/dl (x, 14.4 ± 2.5). Both
were unchanged at 24 hr. Postural rather than
direct drug effects might be invoked to explain
hernoconcentration'"; all patients were supine,
whereas patients receiving drug intravenously
had markedly higher serum concentrations of
bretylium but no greater degree of hemocon-
centration. There were no changes in QRS, Q-T
intervals, or heart rate in electrocardiograms
taken at 24 hr. Mean P-R decreased slightly
(0.158 to 0.151, P = 0.01). All patients toler-
ated the study well. There were no complica-
tions except for postural syncope in one subject
who, despite orders to the contrary, stood to
urinate 4 hr after intravenous bretylium. No in-
jury was sustained.
Discussion
This study extends previous kinetic informa-
tion on bretylium.P: 14. 17. 23 Romhildt et al.
estimated average serum tVz to be 10 hr after
intramuscular injection.P Kuntzman et al. de-
scribed non-first-order elimination during the
first 24 hr after bretylium, with an elimination
tl/z of at least 5 to 6 hr. 17 Holder et al. claimed
bretylium facilitated cardioversion from ven-
tricular fibrillation within minutes of adminis-
4020 30
TIME (Hours)
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10
IL-_----l.__......l....__-C-__'---~
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Fig. 3. Serum concentration-time curves in subject 3
(G. A.) after 5 mg/kg bretylium tosylate intrave-
nously and orally. Ordinate is serum concentration
(Cs) bretylium (ng/ml); abscissa is time (hr).
val O-infinity. This ratio, expressed as a per-
centage (P), indicates virtually total account-
ing for drug within 48 hr after oral doses
(97.0% [4.6%]), and 90% [7.1%] within 48 hr
after intravenous doses.
Determination of elimination rate con-
stants. Serum bretylium concentrations corre-
sponding to times indicated in Table VII were
used to estimate the apparent elimination rate
constants, A\V and Afo. Semi logarithmic plots of
serum concentrations of bretylium were cur-
vilinear up to 24 hr in nine and twenty data sets,
up to 16 hr in seven data sets, up to 12 hr in two
data sets, up to 8 hr in one data set, and up to 6
hr in the other data set. Estimation of elimina-
tion rate constants and half-lifes (tVzs) using
these curvilinear regions would give biased re-
sults. We used only those data points which
appeared to be randomly distributed about a
straight line on semi logarithmic graph paper, or
100
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Table V. Peak serum concentrations of bretylium and time of peak serum concentrations
Oral Intravenous
Peak concentration
I
Time of peak Peak concentration (ng/ml)
Subject (ng/ml) (hr) at end of 0.5-hr infusion
I 91 8.5 1,868
2 84 3 1,134
3 123 4 1,602
4 96 2 2,154
5 50.2 2 1,819
6 56.2 4 2,358
7 38 2 2,436
8 43 I 2,144
9 38 3 1,169
10 143 1 2,277
Mean 76 3.05 1,896
CY(%)* 49 72 24.7
'See footnote to Table I for explanation of ev (%).
Table VI. Areas under serum concentration-time curves
Ave (/J.,g X hr)
ml
Oral Intravenous
Subject 0-48 hr I O-x I p* 0-48 hr I O-x I p*
1 0.886 0.903 98.1 10.395 10.724 96.9
2 0.538 0.553 97.3 6.078 6.324 96.1
3 0.671 0.685 98.0 7.525 7.918 95.0
4 0.272 0.279 97.5 11.520 11.987 96.1
5 0.517 0.522 99.0 11.811 12.720 92.9
6 0.942 1.114 84.6 14.764 17.039 86.6
7 0.340 0.344 98.8 7.098 8.833 80.4
8 0.309 0.309 100.0 15.498 17.442 88.9
9 0.540 0.554 97.5 5.773 6.669 86.6
10 0.781 0.784 99.6 7.353 9.155 80.3
Mean 0.580 0.605 97.0 9.782 10.88 90.0
CV (%)t 40.9 44.8 4.6 36.2 36.3 7.1
•Ave 0-48 hr expressed as a percentage of the estimated AVe 0 - YO.
tSee footnote to Table I for explanation of ev (%).
tration.P Romhildt et al. reported the maximal
antiarrhythmic effect to be delayed until 6 hr,
whereas the antihypertensive effect occurred
after 1 hr. 23 Our study of tissue bretylium kinet-
ics in the dog suggested both peak cardiac
cumulation and peak antifibrillatory effect to be
delayed until 3 to 6 hr. 2 Serum and myocardial
bretylium did not reach pseudoequilibrium until
12 hr, after which parallel elimination occurred
with tV2 of 10.5 hr.
In this study we analyzed for the first time
both intravenous and oral disposition of bre-
tylium in man, and compared the disposition of
the two routes for a full 48 hr. The curvilinear
nature of semilogarithmic plots of serum con-
centration: time for at least 12 hr in most in-
stances suggests that bretylium elimination does
not fit a classic two-compartment open model.
Mean apparent elimination rate constant after
oral administration (AIO = 0.115 hr") was
greater than that after intravenous doses (Aj" =
0.510 hr"). Greater mean renal clearance of
bretylium after oral doses than after intravenous
doses agrees with the differences in elimination
476 Anderson et al.
Table VII. Corresponding serum bretylium
concentrations and times used to estimate the
apparent elimination rate constants, ,\,~v and ,\,ro
Time (hr) after oral
dosing or the end of
infusion
Subject Route 618 112 116124 148
Intravenous X X
Oral X X
2 Intravenous X X X
Oral X X NO
3 Intravenous X X
Oral X X X b X
4 Intravenous X X NO NO
Oral X X NO NO
5 Intravenous X X
Oral X X NO
6 Intravenous X X
Oral X X
7 Intravenous X X
Oral X X X NO
8 Intravenous X X X
Oral X X X X * NO
9 Intravenous X X
Oral X X NO
10 Intravenous X X X
Oral X X NO
NO = Bretylium not detectable in the sample.
'Concentration detectable but not included in estimation of the
rate constant since markedly off trend of other points.
rate and tlfz by route of administration. Renal
clearance of bretylium by both routes is much
higher than creatinine clearance. Measured
renal clearance of bretylium after oral doses
(l,268 ml/min) equals total estimated renal
blood flow. Assuming serum and whole blood
concentrations to be equal, this suggests that
drug is virtually completely cleared from blood
during a single passage through the kidney. 8
The cause of the discrepant elimination after
oral and intravenous bretylium is not clear and
may relate to both concentration-dependent
renal clearance and to route of administration
per se. Our protocol with four urinary collection
periods did not provide sufficient data to de-
termine the quantitative relationship between
urinary excretion rate and serum concentration.
These data did provide some evidence of a non-
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linear relationship between instantaneous uri-
nary excretion rate and the corresponding serum
concentrations but in the urinary excretion
range where a comparison between oral and in-
travenous data was feasible, there were addi-
tional differences between the two routes. It
should be emphasized that clearances as re-
ported are estimated over the entire time inter-
val from zero to infinity after the single doses
(see Appendix). Determining the exact relation-
ship between instantaneous urinary excretion
rates and serum concentrations thus requires
further study.
Experimental evidence suggests an active
transport system for quaternary ammonium
compounds by the renal tubular epithelium and
intestinal mucosa.': 25. 28 A secretory mecha-
nism that becomes saturable with rising serum
concentration has been postulated for these
compounds to explain observed dose depen-
dency and time dependency of disposition.
Such a mechanism might, in part, explain the
relatively slower excretion at the higher con-
centrations after intravenous doses. Another
consideration is that after intravenous bre-
tylium, redistribution of intravascular fluid may
occur in response to higher bretylium concen-
tration and result in lower renal plasma flow,
but differences in creatinine clearance between
intravenous and oral drug were not significant.
Such possibilities as irregular temporal absorp-
tion of drug from the gastrointestinal tract, in-
testinal secretion, or enterohepatic recycling of
drug to explain variation in the initial serum
concentration-time curves after oral drug also
need further investigation.
Our results indicate that if serum is collected
long enough, virtually the entire dose of intra-
venously administered drug is excreted. This
suggests that most, if not all, subjects do not
metabolize bretylium, but excrete it unchanged
in urine. This emphasizes the importance of
renal excretion in determining drug elimination
and should suggest appropriate modification in
dosage when giving bretylium to patients with
renal insufficiency.
Very large values for volumes of distribution
of bretylium indicate it to be highly bound to
tissue in man, but not at all to plasma proteins.
Previous work in experimental animals indi-
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cates extensive bretylium cumulation in sym-
pathetic ganglia and in their postganglionic
nerves, and also in various tissues, particularly
heart, liver, spleen, and kidneys" 21 but it does
not cumulate in the central nervous system."
Limited bretylium absorption after oral dos-
ing is not surprising in view of the low lipid
solubility and fixed positive charge of its
quaternary structure;" This suggests potential
difficulty in the clinical use of an oral formula-
tion. The lower therapeutic range for serum
concentration is not known, but much higher
oral doses will certainly be needed to match the
concentrations after intravenous bretylium. The
disposition of these equivalent, much larger oral
doses of drug should be investigated separately
to evaluate dose-dependent effects in disposi-
tion. Because of the variability of absorption, it
may also be important to determine serum con-
centrations in patients taking bretylium by
mouth,
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Total areas were obtained with equation 3:
I x IT 'AUC = 0 Cdt = 0 Cdt + erlA[ (3)
(4)
The value of f was obtained with equation 5:
f = CW' /CI~ (5)
The value of Fpo was obtained with equation 6
which, in tum, may be obtained from one of the
equations of Kwan and Till.!"
Usually Fpo is estimated from just the first term on
the right-hand side of equation 6, but under those
conditions renal clearance is assumed constant after
intravenous and oral administration. However, the
renal clearance of bretylium in our study did not re-
main constant and equation 6 compensates for this
lack of constancy.
Vdss was estimated directly from the serum
concentration-time data with the equation of Benet
and Galeazzi" shown in our symbolism as equation 7:
(6)Fpo = D!v (AUC)po
Dpo (AUC)!v
(1)
Appendix
Kinetic parameters were estimated as follows (see
also references 5 and 18).
To estimate the area under the serum con-
centration-time curve (AUC), I TCdt , up to the last
sampling time, T, in which the~e was a detectable
concentration, the ordinary trapezoidal rule'" was
used for oral data and the logarithmic trapezoidal
rule'" was used for intravenous data. To estimate the
first moment, I :tCdt, following intravenous admin-
istration, the ordinary trapezoidal rule was used.
The method of least squares was applied to the
natural logarithms of serum concentrations and the
corresponding times to obtained A)o (A)o if oral data
and AIV if intravenous data) using those concen-
tration-time data (see Table II) which appeared to be
log linear. The equation of the straight line is given
below:
in which C is the serum concentration at time t, fnI is
the intercept on the ordinate axis, and A[ is the appar-
ent first-order elimination rate constant. The line-
estimated concentration, CT , at time T was obtained
by substituting T for t in equation 1, then converting
to equation 2:
CT = e(/nl - A,T) (2)
V - D!v .J:7 tCdt
dss - [J,~ Cdt F (7)
.J:r tCdt + C. T + C]
o Al AI
